In last trading session, Gritstone bio Inc. (NASDAQ:GRTS) saw 0.43 million shares changing hands with its beta currently measuring 0.64. Company’s recent per share price level of $3.25 trading at $0.07 or 2.20% at ring of the bell on the day assigns it a market valuation of $274.98M. That closing price of GRTS’s stock is at a discount of -343.69% from its 52-week high price of $14.42 and is indicating a premium of 47.38% from its 52-week low price of $1.71. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.87 million shares which gives us an average trading volume of 762.49K if we extend that period to 3-months.
For Gritstone bio Inc. (GRTS), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.20. Splitting up the data highlights that, out of 5 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.41 in the current quarter.
Gritstone bio Inc. (NASDAQ:GRTS) trade information
Upright in the green during last session for gaining 2.20%, in the last five days GRTS remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $3.25 price level, adding 9.72% to its value on the day. Gritstone bio Inc.’s shares saw a change of -74.73% in year-to-date performance and have moved -0.31% in past 5-day. Gritstone bio Inc. (NASDAQ:GRTS) showed a performance of 32.65% in past 30-days. Number of shares sold short was 5.35 million shares which calculate 10.23 days to cover the short interests.
Gritstone bio Inc. (GRTS) estimates and forecasts
Statistics highlight that Gritstone bio Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 83.62% of value to its shares in past 6 months, showing an annual growth rate of -43.16% while that of industry is 4.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -13.90% in the current quarter and calculating -10.80% decrease in the next quarter. This year revenue growth is estimated to fall -60.20% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $3.26 million for the same. And 4 analysts are in estimates of company making revenue of $3.28 million in the next quarter that will end on Dec 2022. Company posted $2.61 million and $3.06 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 24.70% while estimating it to be 7.00% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.50% during past 5 years.
Gritstone bio Inc. is more likely to be releasing its next quarterly report between November 01 and November 07 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Gritstone bio Inc. (NASDAQ:GRTS)’s Major holders
Insiders are in possession of 2.97% of company’s total shares while institution are holding 48.30 percent of that, with stock having share float percentage of 49.78%. Investors also watch the number of corporate investors in a company very closely, which is 48.30% institutions for Gritstone bio Inc. that are currently holding shares of the company. Redmile Group, LLC is the top institutional holder at GRTS for having 6.95 million shares of worth $16.83 million. And as of Jun 29, 2022, it was holding 9.55% of the company’s outstanding shares.
The second largest institutional holder is Frazier Life Sciences Management, L.P., which was holding about 5.24 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 7.19% of outstanding shares, having a total worth of $12.67 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 2.06 million shares of worth $4.97 million or 2.82% of the total outstanding shares. The later fund manager was in possession of 0.73 million shares on Jun 29, 2022, making its stake of worth around $1.77 million in the company or a holder of 1.00% of company’s stock.